Status:

TERMINATED

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.

Eligibility Criteria

Inclusion

  • For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
  • Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1
  • Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Ability to swallow tablets
  • Adequate bone marrow and organ function, as defined by the protocol

Exclusion

  • Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll)
  • Ocular melanoma
  • Any significant acute or chronic medical illness
  • Prior malignancy
  • Other active malignancy requiring concurrent intervention
  • Prior organ allograft or allogeneic bone marrow transplantation
  • Participants with active, known, or suspected autoimmune disease
  • Requirement for daily supplemental oxygen
  • Uncontrolled or significant cardiovascular disease
  • Pre-existing liver disease
  • Gastrointestinal disease known to interfere with absorption
  • Other protocol defined inclusion/exclusion criteria could apply

Key Trial Info

Start Date :

November 27 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 28 2018

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT03351231

Start Date

November 27 2017

End Date

August 28 2018

Last Update

August 26 2020

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

University Of Alabama At Birmingham

Birmingham, Alabama, United States, 35294-3300

2

Hoag Memorial Hospital Presbyterian

Los Angeles, California, United States, 90033

3

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90033

4

Local Institution

Baltimore, Maryland, United States, 21287